cis-Urocanic acid

CAS No. 7699-35-6

cis-Urocanic acid ( (Z)-Urocanic acid; cis-UCA; (E)-Urocanic acid; (Z)-Imidazole-4-acrylic acid; (Z)-3-(1H-Imidazol-5-yl)acrylic acid )

Catalog No. M26118 CAS No. 7699-35-6

cis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 417 Get Quote
10MG 615 Get Quote
25MG 963 Get Quote
50MG 1305 Get Quote
100MG 1755 Get Quote
500MG 3501 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    cis-Urocanic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    cis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.
  • Description
    cis-Urocanic acid is a 5-HT2A receptor agonist (Kd: 4.6 nM). It is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor.(In Vitro):Treatment with 100 μg/mL cis-Urocanic acid completely suppresses IL-6 and IL-8 secretion decreases caspase-3 activity and improves cell viability against UV-B irradiation. No significant effects on IL-6 or IL-8 secretion, caspase-3 activity, or viability of the non-irradiated cells are observed with 100 μg/mL cis-Urocanic acid in both cell types .
  • Synonyms
    (Z)-Urocanic acid; cis-UCA; (E)-Urocanic acid; (Z)-Imidazole-4-acrylic acid; (Z)-3-(1H-Imidazol-5-yl)acrylic acid
  • Pathway
    Endocrinology/Hormones
  • Target
    5-HT Receptor
  • Recptor
    Alkyl-Chain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    7699-35-6
  • Formula Weight
    138.1
  • Molecular Formula
    C6H6N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC(=O)\C=C/c1cnc[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.
molnova catalog
related products